Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (231-240 of 367) with videos related to

Pageof 37
Sort By:
Cancer|October 28, 2011
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical studyMarkus Joerger, Sjaak A Burgers, Paul Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2023
A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical DiagnosticsKarlijn Hummelink, Renaud Tissier, Linda J W Bosch, et al.
Plos One|March 6, 2008
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential targetMariëlle I Gallegos Ruiz, Karijn Floor, Paul Roepman, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trialBen J Slotman, Corinne Faivre-Finn, Harm van Tinteren, et al.
American Journal of Respiratory and Critical Care Medicine|February 10, 2007
The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epitheliumRemco M van den Berg, Harm van Tinteren, Nico van Zandwijk, et al.
British Journal of Cancer|May 15, 2024
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancerUmberto Malapelle, Natasha Leighl, Alfredo Addeo, et al.
American Journal of Respiratory and Critical Care Medicine|August 15, 2015
Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial LesionsRobert A A van Boerdonk, Illaa Smesseim, Daniëlle A M Heideman, et al.
Journal of the National Cancer Institute|March 22, 2007
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancerJan P van Meerbeeck, Gijs W P M Kramer, Paul E Y Van Schil, et al.
Oncoimmunology|August 27, 2024
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL productsSuzanne M Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 8, 2016
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patchesEvelyn E C de Jong, Wouter van Elmpt, Ralph T H Leijenaar, et al.
Pageof 37

Showing results (231-240 of 367) with videos related to

Sort By:
Pageof 37
Cancer|October 28, 2011
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical studyMarkus Joerger, Sjaak A Burgers, Paul Baas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2023
A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical DiagnosticsKarlijn Hummelink, Renaud Tissier, Linda J W Bosch, et al.
Plos One|March 6, 2008
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential targetMariëlle I Gallegos Ruiz, Karijn Floor, Paul Roepman, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trialBen J Slotman, Corinne Faivre-Finn, Harm van Tinteren, et al.
American Journal of Respiratory and Critical Care Medicine|February 10, 2007
The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epitheliumRemco M van den Berg, Harm van Tinteren, Nico van Zandwijk, et al.
British Journal of Cancer|May 15, 2024
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancerUmberto Malapelle, Natasha Leighl, Alfredo Addeo, et al.
American Journal of Respiratory and Critical Care Medicine|August 15, 2015
Close Surveillance with Long-Term Follow-up of Subjects with Preinvasive Endobronchial LesionsRobert A A van Boerdonk, Illaa Smesseim, Daniëlle A M Heideman, et al.
Journal of the National Cancer Institute|March 22, 2007
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancerJan P van Meerbeeck, Gijs W P M Kramer, Paul E Y Van Schil, et al.
Oncoimmunology|August 27, 2024
Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL productsSuzanne M Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 8, 2016
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patchesEvelyn E C de Jong, Wouter van Elmpt, Ralph T H Leijenaar, et al.
Pageof 37